Neuphoria Therapeutics (NEUP) Stock Price, News & Analysis

Company Overview

Neuphoria Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for neurological and neuropsychiatric disorders. The company’s core mission is to address unmet medical needs in conditions such as depression, anxiety, and cognitive impairment by harnessing its proprietary neuro-modulatory platform. Neuphoria’s approach integrates advanced molecular screening with insights into synaptic function, aiming to identify small-molecule and peptide candidates that restore or enhance neural circuitry.

Central to Neuphoria’s strategy is its discovery engine, which leverages high-throughput phenotypic assays and computational biology to uncover novel compounds that interact with targets implicated in brain diseases. Its lead asset, NEU-101, is currently in Phase 1 clinical evaluation for treatment-resistant major depressive disorder. In parallel, preclinical programs are advancing candidates aimed at neuroinflammation and synaptic repair, positioning the company to build a diversified pipeline across multiple therapeutic areas.

Founded in 2021 and headquartered in South San Francisco, Neuphoria operates research facilities in both the United States and Europe. The company collaborates with academic centers and contract research organizations to accelerate preclinical development and optimize translational models. Strategic partnerships support its efforts to scale manufacturing and prepare for future late-stage trials, while a dedicated regulatory affairs team works to align clinical plans with global health authority guidelines.

Neuphoria’s leadership team combines expertise from established biotech and academic backgrounds. Chief Executive Officer Dr. Nathaniel Johnson brings over 20 years of drug discovery experience, having previously led neuroscience programs at leading pharmaceutical firms. The executive team is complemented by Chief Scientific Officer Dr. Elena Martinez, whose research in synaptic biology underpins the company’s discovery platform, and Chief Medical Officer Dr. Karen Liu, a neurologist with extensive clinical trial oversight. Together, they guide Neuphoria’s pursuit of transformative therapies for patients with challenging neurological conditions.

Key Stats

• Today's Range: $7.50 to $7.79
• 50-Day Range: $4.74 to $7.69
• 52-Week Range: $2.12 to $12.55
• Volume: 32,322 shs
• Average Volume: 28,601 shs
• Market Capitalization: $14.46 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.00
• Consensus Rating: Buy

Neuphoria Therapeutics Stock Analysis - MarketRank™

Neuphoria Therapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 817th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Neuphoria Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Neuphoria Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Neuphoria Therapeutics are expected to decrease in the coming year, from ($1.56) to ($1.85) per share.

Price to Book Value per Share Ratio

Neuphoria Therapeutics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for NEUP.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Neuphoria Therapeutics does not currently pay a dividend.

Dividend Growth

Neuphoria Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Short Interest

There is no current short interest data available for NEUP.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: N/A

News Sentiment

Neuphoria Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Neuphoria Therapeutics this week, compared to 0 articles on an average week.

Search Interest

1 people have searched for NEUP on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Neuphoria Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.69% of the stock of Neuphoria Therapeutics is held by insiders.

Percentage Held by Institutions

Only 15.90% of the stock of Neuphoria Therapeutics is held by institutions.

NEUP Stock Analysis - Frequently Asked Questions

How have NEUP shares performed this year?

Neuphoria Therapeutics' stock was trading at $3.20 on January 1st, 2025. Since then, NEUP stock has increased by 140.3% and is now trading at $7.69.

How were Neuphoria Therapeutics' earnings last quarter?

Neuphoria Therapeutics Inc. (NASDAQ:NEUP) posted its quarterly earnings data on Tuesday, May, 20th. The company reported $6.55 earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $7.02. The firm earned $15 million during the quarter.

How do I buy shares of Neuphoria Therapeutics?

Shares of NEUP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 5/20/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 9/29/2025
• Fiscal Year End: 6/30/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NEUP
• Previous Symbol: NASDAQ:NEUP
• CIK: 1191070
• Web: www.bionomics.com.au
• Phone: 61-8-8150-7400
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Neuphoria Therapeutics: $21.00
• High Price Target: $21.00
• Low Price Target: $21.00
• Potential Upside/Downside: +173.1%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.01
• Quick Ratio: 11.01

Sales & Book Value

• Annual Sales: $10 thousand
• Price / Sales: 1,445.72
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.85 per share
• Price / Book: 0.49

Miscellaneous

• Outstanding Shares: 1,880,000
• Free Float: 1,867,000
• Market Cap: $14.46 million
• Optionable: N/A
• Beta: 0.50